A Phase 2 Study of Defactinib and Avutometinib, in Combination With Nivolumab for Patients With Anti-PD1 Refractory LKB1-Mutant Advanced Lung Adenocarcinoma

This study tests a new combination of three drugs for patients with advanced lung cancer that has stopped responding to standard immunotherapy. By targeting specific protein signals that help cancer survive, researchers hope to find a more effective way to stop tumor growth.

This trial is for patients with a specific type of advanced lung cancer (adenocarcinoma) that has an 'LKB1' genetic mutation. You must have already tried immunotherapy and chemotherapy, and your cancer must have worsened despite those treatments.

Participants will receive a combination of three medications and undergo regular health monitoring, including scans, blood tests, and potentially tissue biopsies. These tests help doctors keep a close eye on your health and see how your cancer is responding to the new treatment.

The study is currently recruiting new participants at medical centers in Atlanta, Georgia. Because this is a clinical trial, your care team will work closely with you to manage your health throughout the process.